RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Extrahepatic cholangiocarcinoma is a malignant tumor that is highly malignant and difficult
to diagnose and treat early. Endobiliary radiofrequency ablation (RFA) has been reported to
be a beneficial treatment option for palliation of malignant biliary strictures. Within the
bile duct, RFA appears to be safe and may result in decreased tumor ingrowth. To date, little
is known about the role of the addition of systemic chemotherapy to RFA for
cholangiocarcinoma. The aim of this study is to compare the efficacy and safety of RAF
combined with Gemcitabine and S-1 in patients with unresectable cholangiocarcinoma.
Phase:
N/A
Details
Lead Sponsor:
First People's Hospital of Hangzhou
Collaborators:
Changhai Hospital Chinese Academy of Medical Sciences Eastern Hepatobiliary Surgery Hospital Hangzhou Cancer Hospital Xijing Hospital